The NIH Guide announces scientific initiatives and provides policy and administrative information to individuals and organizations who need to be kept informed of opportunities, requirements, and changes in extramural programs administered by the National Institutes of Health.

Vol. 19, No. 45
December 14, 1990
NOTICES

PROGRAM INCOME EARNED UNDER RESEARCH GRANTS ........................................ 1
Public Health Service
National Institutes of Health
Alcohol, Drug Abuse, and Mental Health Administration
Index: PUBLIC HEALTH SERVICE
     NATIONAL INSTITUTES OF HEALTH
     ALCOHOL, DRUG ABUSE, AND MENTAL HEALTH ADMINISTRATION

NATIONAL WORKSHOPS ON "PROTECTION OF HUMAN SUBJECTS" ......................... 2
National Institutes of Health
Food and Drug Administration
Index: NATIONAL INSTITUTES OF HEALTH
     FOOD AND DRUG ADMINISTRATION

REVISED SALARY CEILING ON CAREER AWARDS ........................................... 4
National Institutes of Health
Index: NATIONAL INSTITUTES OF HEALTH

DATED ANNOUNCEMENTS

NIH SMALL INSTRUMENT GRANTS PROGRAM .................................................... 4
National Institutes of Health
Index: NATIONAL INSTITUTES OF HEALTH

NOTICES OF AVAILABILITY (RFPs AND RFAs)

TOXICOLOGY OF AIDS THERAPEUTICS (RFP) ................................................ 5
National Institute of Environmental Health Sciences
Index: ENVIRONMENTAL HEALTH SCIENCES

CLINICAL RESEARCH CENTERS ON HEAD INJURY, SPINAL CORD INJURY,
AND CNS TRAUMA (RFA NS-91-02) ......................................................... 5
National Institute of Neurological Disorders and Stroke
Index: NEUROLOGICAL DISORDERS, STROKE

ONGOING PROGRAM ANNOUNCEMENTS

RESEARCH TRAINING AND CAREER DEVELOPMENT AWARDS IN DIABETES,
ENDOCRINOLOGY, AND METABOLIC DISEASES (PA-91-15) ............................. 7
National Institute of Diabetes and Digestive and Kidney Diseases
Index: DIABETES, DIGESTIVE DISEASES, KIDNEY DISEASES

NOTICES

PROGRAM INCOME EARNED UNDER RESEARCH GRANTS

P.T. 34; K.W. 1014006

Public Health Service
National Institutes of Health
Alcohol, Drug Abuse, and Mental Health Administration

Public Health Service (PHS) policy requires applicants for PHS research grants to include in their grant applications an estimate of the amount and source of program income (defined below) expected to be generated as a result of the project for which support is being sought. The specific policies that govern the treatment of program income under research grants are set forth in the Interim Update to the 10/1/90 edition of the PHS Grants Policy Statement (GPS). The contents of the Interim Update, which was issued on 11/15/90 as part of PHS Grants Policy Memorandum Number 54, also will be included in the formal GPS revisions expected to be issued on or about 1/1/91.

Program income is gross income earned by a grant recipient from activities part or all of which is borne as a direct cost by the grant. Examples of program income include:

- Fees earned from services performed under the grant, such as those resulting from laboratory drug testing.
- Rental or usage fees, such as those earned from fees charged for use of computer equipment purchased with grant funds.
- Third-party patient reimbursement for hospital or other medical services, such as insurance payments for patients where such reimbursement occurs because of the grant-supported activity.
- Funds generated by the sale of commodities, such as tissue cultures, cell lines, or research animals.

The current application Forms PHS 398 and 2590 (Revised 10/88, Reprinted 9/89) will undergo a general revision to accommodate, among other changes, the required information on program income. However, until that occurs, research grant applications must address the subject as follows:

- For both competing applications (Form PHS 398) and noncompeting continuation applications (Form PHS 2590), the OTHER SUPPORT page must indicate yes or no whether program income is anticipated during the period(s) for which grant support is requested. If the answer is "yes", the amount and source(s) of such income by budget period also must be indicated.

The above requirement begins with:

- New (Type 1) applications submitted for the 2/1/91 receipt date.
- Competing Continuation (Type 2) applications submitted for the 3/1/91 receipt date.
- Noncompeting Continuation (Type 5) applications for budget periods beginning 4/1/91.

Consistent with page 8-9 of the GPS (as updated 11/15/90), program income earned under research grants is to be treated by grantees according to one of the following alternatives prescribed by the PHS awarding component:

A. Additional Costs (Regardless of Amount)

The income is used for costs that are in addition to the allowable costs of the grant but that nevertheless further the objectives of the statute under which the grant was made. This alternative routinely will be applied to those research grants that are subject to the expanded grant authorities set forth on pages 8-3 through 8-5 of the GPS (as updated 11/15/90).

B. Deduction (Regardless of Amount)

The income is used for allowable costs of the grant but reduces (rather than increases) the level of funds committed to the grant project. This alternative is applied most commonly to program income earned under...
nonresearch grants for health services projects, but its use is not limited solely to such projects.

C. Additional Costs (First $25,000) and Deduction (Amounts in Excess of $25,000)

This combination of alternatives A. and B., above, represents the routine treatment of program income for those research grants that are not subject to the expanded grant authorities.

D. Other

This acknowledges the latitude of PHS awarding components to prescribe "other" methods of treating program income when deemed appropriate to the particular circumstances.

In all cases the Notice of Grant Award (Form PHS 1533) will reflect the approved treatment of any program income, whether anticipated at the time of award or not. PHS grants management staff may contact applicants prior to award to discuss the treatment of program income in specific instances. Applicants with questions concerning any aspect of this topic are encouraged to contact the Grants Management Officer of the appropriate PHS awarding component.

Regardless of the disposition instructions on the Notice of Grant Award, all program income earned during the budget period must be identified on the Financial Status Report.

NATIONAL WORKSHOPS ON "PROTECTION OF HUMAN SUBJECTS"

P.T. 42; K.W. 0783005

National Institutes of Health
Food and Drug Administration

The National Institutes of Health (NIH) and the Food and Drug Administration (FDA) are continuing to sponsor a series of workshops on responsibilities of researchers, Institutional Review Boards (IRBs), and institutional officials for the protection of human subjects in research. The workshops are open to everyone with an interest in research involving human subjects. The meetings should be of special interest to those persons currently serving or about to begin serving as a member of an IRB. Issues discussed at these workshops are relevant to all other Public Health Service agencies. The current schedule includes the following:

I. SOUTHWEST WORKSHOP

DATES: February 4-5, 1991

WORKSHOP SITE:
Meridien Hotel
50 Third Street
San Francisco, CA 94103

SPONSOR:
University of California at San Francisco
Box 0400
San Francisco, CA 94143

REGISTRATION CONTACT:
Ms. Phyllis Colbert
Workshop Contact Person
University of California at San Francisco
Box 0400
San Francisco, CA 94143
Telephone: (415) 476-1881

TOPIC: "The Use of Human Subjects in Research: AIDS as a Model of Complexity"

II. MIDEAST WORKSHOP

DATES: March 4-5, 1991
WORKSHOP SITE:
Friday Center
Laurel Hill Parkway
Chapel Hill, NC 27599-1020

SPONSORS:
University of North Carolina at Chapel Hill
300 Bynum Hall
Chapel Hill, NC 27599-4100

Shaw University
118 E. South Street
Raleigh, NC 27611

REGISTRATION CONTACT:
Mr. Al Dawson
Director
Friday Center
Laurel Hill Parkway
C. B. 1020
Chapel Hill, NC 27599-1020
Telephone: (919) 962-1106

TOPIC: "Interpreting the Federal Code for the Protection of Human Subjects"

III. MIDWEST WORKSHOP

DATES: April 11-12, 1991

WORKSHOP SITE:
Hyde Park Hilton
4900 Lake Shore Drive
Chicago, IL 60615

SPONSORS:
University of Chicago
970 East 58th Street
Chicago, IL 60637

Chicago State University
95th Street at King Drive
Chicago, IL 60628

REGISTRATION CONTACT:
Mr. Arnold L. Aronoff
Associate Director
Faculty and Administrative Services
University Research Administration
University of Chicago
970 East 58th Street
Chicago, IL 60637
Telephone: (312) 702-8669

TOPIC: "Cultural Diversity, Ethics, and Research: A Workshop on Human Subject Protection"

NIH/FDA have planned national human subject protections workshops in other parts of the United States. For further information regarding these workshops contact:

Darlene Marie Ross
Executive Assistant for Education
Division of Human Subject Protections
Office for Protection from Research Risks
National Institutes of Health
9000 Rockville Pike
Bldg. 31, Room 5B43B
Bethesda, MD 20892
Telephone: (301) 496-8101
REVISED SALARY CEILING ON CAREER AWARDS

P.T. 34; K.W. 1014002, 1014006

National Institutes of Health

Beginning with awards made from Fiscal Year 1991 funds, the ceiling for reimbursement of the candidates' base salary on all career awards will be $50,000. Under this policy, the NIH contribution to the base salary will be consistent with the grantee institution's salary scale up to a maximum of $50,000. At this time the salary increase will affect the following awards:

<table>
<thead>
<tr>
<th>Name of the Award</th>
<th>Activity Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Special Emphasis Research Career Award</td>
<td>K01</td>
</tr>
<tr>
<td>Academic Award</td>
<td>K07</td>
</tr>
<tr>
<td>Clinical Investigator Award</td>
<td>K08</td>
</tr>
<tr>
<td>Physician Scientist Award</td>
<td>K11</td>
</tr>
<tr>
<td>Physician Scientist Award (program)</td>
<td>K12</td>
</tr>
<tr>
<td>Minority School Faculty Development Award</td>
<td>K14</td>
</tr>
<tr>
<td>Dental Scientist Award</td>
<td>K15</td>
</tr>
<tr>
<td>Dental Scientist Award (program)</td>
<td>K16</td>
</tr>
</tbody>
</table>

The salary ceiling on Research Career Development Awards (K04) was raised to $50,000 in Fiscal Year 1990.

DATED ANNOUNCEMENTS

NIH SMALL INSTRUMENTS GRANTS PROGRAM

P.T. 34; K.W. 0735000

National Institutes of Health

Application Receipt Date: February 13, 1991

BACKGROUND

In its appropriation for the NIH for Fiscal Year 1987, the Congress included $16 million to be spent by the respective NIH Institutes and Centers to fund grants for the purchase of small instruments costing between $5,000 and $60,000. This action was in response to several recent studies that indicate that the state of biomedical research instrumentation had seriously eroded over the last ten years and that this situation was retarding the progress of biomedical research. The most significant need identified in these studies was for the relatively low-cost pieces of equipment in the price range of approximately $5,000 to $60,000. The Congress in subsequent years has continued to provide funds for this activity.

Approximately $16 million is available for small instrumentation grants this year.

ELIGIBILITY AND TERMS OF AWARD

Each institution that received support under the Biomedical Research Support Grant (BRSIG) Program in Fiscal Year 1990 and currently has active NIH research grants is eligible to apply. Only one application may be submitted from each eligible institution or organizational component. Each institution may establish its own procedures for identifying equipment requests to be included.

The small instrumentation award will be restricted to the purchase of equipment costing between $5,000 and $60,000. Awards will be made on or before September 30, 1991. The amount of the award will be based upon a percentage of the institution's Biomedical Research Support Grant award for Fiscal Year 1990 or $5,000, whichever is greater. Specific funding decisions will depend on available appropriations as well as the appropriateness of the request. Institutions will be notified of the maximum amount for which they may apply.

METHOD OF APPLYING

Letters of instruction to eligible institutions were mailed on November 28, 1990.
Completed applications must be received by February 13, 1991.

Investigators interested in participating in their institution's application must contact the institution's Biomedical Research Support Grant Program Director. Institutional officials who expect to be involved in preparing an application are requested to review the letter of instructions prior to contacting NIH. For additional information contact:

Office of Special Programs and Initiatives
Office of Extramural Programs
National Institutes of Health
Building 31, Room 5B44
Bethesda, MD 20892
Telephone: (301) 496-1968

NOTICES OF AVAILABILITY (RFPs AND RFAs)

TOXICOLOGY OF AIDS THERAPEUTICS

RFP AVAILABLE: NIH-ES-91-02
P.T. 34; K.W. 0715008, 0740012, 0740020, 1007009

National Institute of Environmental Health Sciences

The National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health (NIH), is soliciting proposals from offerors having the capability to conduct subchronic general and reproductive/developmental toxicity studies in rodents exposed to AIDS therapeutics. Toxicologic evaluation of a specific AIDS therapeutic will involve the evaluation of the therapeutic, alone or in combination, in a reproductive/developmental toxicity study in rats and/or a general toxicity study in rats and mice. Based on both the results of these studies and the current status of research being conducted on the particular therapeutic being evaluated, a decision will be made as to whether the therapeutic, alone or in combination, shall be evaluated further. If reproductive/developmental toxicity evaluation is to continue, a study plan will be designed and performed by the reproductive/developmental group of the Systems Toxicity Branch of NIEHS. If general toxicity evaluation is to continue, a study plan shall be designed and performed by the contractor for a 13-week and/or 6-month study in rats and/or mice. The contractor will be required to perform approximately 5 studies for year 1, 5 studies for year 2, 3 studies for year 3, 6 studies for year 4, and 1 study for year 5. The number and type of studies may vary from year to year, depending upon the needs of the NIEHS. The estimated issuance date of RFP NIH-ES-91-02 is December 18, 1990 and responses will be due to be received 45 days thereafter. The NIEHS expects to make one award from this solicitation.

Requests for the RFP should reference RFP NIH-ES-91-02 and should be forwarded to:

National Institute of Environmental Health Sciences
Contracts and Procurement Management Branch, OM
ATTN: Jo Ann Lewis
79 T.W. Alexander Drive, 4401 Building
P.O. Box 12874
Research Triangle Park, NC 27709

CLINICAL RESEARCH CENTERS ON HEAD INJURY, SPINAL CORD INJURY, AND CNS TRAUMA

RFA AVAILABLE: NS-91-02
P.T. 34; K.W. 0715027, 0715210, 0705010, 0705055

National Institute of Neurological Disorders and Stroke

Letter of Intent Receipt Date: March 1, 1991
Application Receipt Date: April 26, 1991

PURPOSE

The National Institute of Neurological Disorders and Stroke (NINDS) invites applications for Head Injury Clinical Research Centers, Spinal Cord Injury Clinical Research Centers, Central Nervous System (CNS) Trauma Clinical Research Centers, or feasibility (exploratory) grants for the development of...
such centers. The purpose of this Request for Applications (RFA) is to promote research that will lead to improved clinical treatment, and to increase clinical research on the restoration and preservation of function after head or spinal cord injury.

EXPERTISE AND ELIGIBILITY

The Center Director or Principal Investigator must be active in a clinical or basic discipline related to central nervous system trauma, and have demonstrated capabilities for developing and directing an integrated research program. The research projects included in the centers should be conducted by scientists or clinicians representing a variety of disciplines, who will relate to each other so that new scientific and clinical leads may be developed and utilized. Applicants must document the existence of, or potential for, ongoing basic, applied, and clinical research related to CNS trauma research facilities in neuroscience; clinical facilities that demonstrate the ability to account for patients suffering CNS injuries; and plans for the further development of individual investigators, fellows, or clinicians in specialized techniques or procedures relevant to research in CNS trauma.

SPECIAL INSTRUCTIONS FOR INCLUSION OF WOMEN AND MINORITIES IN CLINICAL RESEARCH STUDIES

For projects involving clinical research, NIH requires applicants to give special attention to the inclusion of women and minorities in study populations. If women or minorities are not included in the study populations for clinical studies, a specific justification for this exclusion must be provided. Applications without such documentation will not be accepted for review.

MECHANISM OF SUPPORT

The support mechanism for this program will be the research center grant (P50) or the exploratory (feasibility) grant (P20). Center grants will be awarded for up to five years, renewable; feasibility grants will be awarded for up to three years, not renewable. Research center grants (P50) may not exceed annual direct costs of $750,000 for each of five years; exploratory grants (P20) may not exceed annual direct costs of $250,000 for each of three years. The NINDS expects to make up to three awards for center grants and (or) up to ten awards for exploratory grants, depending upon availability of funds.

REVIEW PROCEDURES

Upon receipt, applications will be reviewed by NINDS staff to determine administrative and programmatic responsiveness to this RFA. Applications judged unresponsive will be returned to the applicant. All applications that are complete and responsive may be subjected to a triage by an NINDS review group to determine relative scientific merit among the applications. The NINDS will administratively withdraw those applications judged to be noncompetitive for award. Those applications judged to be competitive for award will be further reviewed for scientific and technical merit by a peer review group convened by NINDS. No site visits will be made. A final level of review will be by the National Advisory Neurological Disorders and Stroke Council.

METHOD OF APPLYING

Letter of Intent. The NINDS urges applicants to submit a letter of intent including: name and address of the Principal Investigator, names and addresses of co-investigators responsible for each project within the center; descriptive titles of individual projects and required components; and identification of collaborating institutions. Letters should specify whether the application will be for the research center (P50) or for the feasibility grant (P20). A letter of intent is not binding, does not enter into the review of a subsequent application, and is not a precondition for an award.

Format of Applications. All applicants will use form PHS 398 (revised 10/88). Applicants should use the format as described in the NINDS brochure "Application Guidelines: Project Program and Clinical Research Center Grants" (revised 10/89), which may be obtained from Dr. Mary Ellen Michel at the address below. To identify the application as a response to this RFA, check "yes" on item 2 of page 1 of the application form and enter the title "NINDS: HEAD, SPINAL CORD INJURY CLINICAL RESEARCH CENTERS" and the RFA number NS-91-02. All applications must be received by April 26, 1991. An application not received by this date will be ineligible for consideration. Awards will be made on or before September 30, 1991.
INQUIRIES

A copy of the complete RFA, including review criteria and application instructions, may be obtained from this issue of the E-Guide or contacting:

Dr. Mary Ellen Michel
Division of Stroke and Trauma, NINDS
Federal Building, Room 8A13
Bethesda, MD 20892
Telephone: (301) 496-4226

The program to which the intended grants relate is described in the Catalog of Federal Domestic Assistance, entry numbers 93.853, "Clinical Research Related Neurological Disorders" and 93.854, "Biological Basis Research in the Neurosciences". Grants will be awarded under the authority of the Public Health Service Act, Title IV, Section 301 (Public Law 78-410, as amended; 42 USC 2411, and administered under PHS grant policies and Federal Regulations 42 CFR Part 52 and 45 CFR Part 74. This program is not subject to the intergovernmental review requirements of Executive Order 12372 or Health Systems Agency review.

ONGOING PROGRAM ANNOUNCEMENTS

RESEARCH TRAINING AND CAREER DEVELOPMENT AWARDS IN DIABETES, ENDOCRINOLOGY, AND METABOLIC DISEASES

PA: PA-91-15
P.T. 22, 34; K.W. 0715075, 0715135, 0785050, 1002004, 1002019, 0710070
National Institute of Diabetes and Digestive and Kidney Diseases

BACKGROUND AND SCOPE

The intention of this Program Announcement is to reemphasize the Division of Diabetes, Endocrinology, and Metabolic Diseases' commitment to increasing the number of biomedical investigators who are conducting high-quality research in the areas of diabetes, endocrinology, and metabolic diseases. The Division encourages all individuals, and especially underrepresented minorities, to submit applications.

Increasingly, problems in diabetes, endocrinology, and metabolism require interdisciplinary approaches. Thus, the Division wishes to encourage applicants for research training and career development support to develop expertise in areas such as molecular biology, cell biology, structural biology, immunology, genetics, and epidemiology as well as in diabetes, endocrinology, and metabolism or metabolic diseases, including cystic fibrosis. This support for professional development may be used to acquire proficiency in sophisticated techniques such as methods for study of protein structure/function, measurement of very low levels of biologically-active molecules, gene transfer techniques, and measurement of ion transport. Applicants seeking to develop such expertise may wish to have mentors in diabetes, endocrinology, or metabolic diseases as well as in another relevant discipline.

Investigators should be aware that NIH requires applicants to give added attention, where feasible and appropriate, to the inclusion of minorities and women in study populations. Gender and minority population differences should be noted and analyzed wherever possible. If minorities and/or women are not included in a given study, a clear reason for their absence must be provided. Merely including an arbitrary number of minority group and women participants in a given study is insufficient to guarantee generalization of results.

Suggestions for interdisciplinary training and career development include but are not limited to:

- Cell biology and endocrinology to investigate the regulation of growth and proliferation of endocrine cells, including pancreatic islets, and the pathophysiology of benign endocrine neoplasms such as thyroid nodules, goiter, and pituitary adenomas;
- Neurobiology and endocrinology to investigate the role of steroid and peptide hormones in the brain and hormonal involvement in disorders such as stress, depression, and Alzheimer's disease;
Developmental biology and endocrinology to study the role of hormones and growth factors in growth and development and in cellular differentiation;

Immunology and endocrinology to investigate the pathogenesis of autoimmune endocrine disorders including Insulin Dependent Diabetes Mellitus, Graves' disease, thyroiditis, and Addison's disease;

Molecular biology and endocrinology to study hormonal regulation of gene expression;

Bone biology and endocrinology to investigate the role of hormones, cytokines, and growth factors in regulation of cell growth and mineralization;

Structural biology and endocrinology to explore at the molecular level the mechanism of hormone action, hormone receptor interactions, and intracellular signaling;

Pharmacology and cystic fibrosis to develop drugs efficacious in cystic fibrosis;

Membrane biochemistry and physiology to explore the molecular basis of defective ion transport in cystic fibrosis;

Molecular biology and cystic fibrosis to develop cell and animal models for study of pathophysiology and therapy of cystic fibrosis, ultimately to explore the possibility of gene therapy;

Genetics and diabetes to investigate the genetic basis of Insulin-Dependent and Noninsulin-Dependent Diabetes Mellitus;

Structural biology and human genetics to investigate the development or application of macromolecular X-ray diffraction and NMR methods, computer-assisted modeling, and molecular dynamics or mechanics simulations to studies of enzyme function, molecular biology, molecular genetics, and/or biochemical genetics of inborn errors of metabolism in model systems and humans;

Cellular biology and human genetics to investigate intercellular and intracellular peptide/protein transport as they pertain to the understanding of human genetic metabolic diseases in model systems and humans;

Neurobiology and human genetics to investigate similarities and differences in metabolic processes between various organ or cell systems and the nervous system, as well as the neurologic implications of abnormal metabolism in human genetic metabolic diseases;

Wide bore and whole body magnetic resonance spectroscopy and imaging of metabolic processes.

MECHANISMS OF SUPPORT

Several mechanisms exist that will support the professional development of individuals who can advance research in these areas. Each mechanism is tailored to a particular stage of the investigator's career. The existing mechanisms are: Individual Fellowships (F32, F33); Physician Scientist Award (PSA-K11); Clinical Investigator Award (CIA-K08); and Research Career Development Award (RCDA-K04). Physician investigators are encouraged to use the PSA and CIA to develop expertise in basic and clinical research.

It is imperative that such a training or career development program equip the developing physician-scientist to become an independent investigator capable of designing and executing rigorous research protocols carefully crafted to examine a hypothesis. Ideally, such investigators should be able to integrate patient-oriented and laboratory-oriented research methods to address questions related to the physiology and pathophysiology of diabetes, endocrinology, and metabolic diseases, including cystic fibrosis.

The support mechanisms for training and research career development awards are summarized in this announcement. Detailed guidelines for each of the mechanisms can be obtained from the office of sponsored programs at most research institutions or from the Division of Research Grants, NIH, (301) 496-7441. Only U.S. citizens and non-citizen nationals are eligible for support under these programs.
A. INDIVIDUAL NATIONAL RESEARCH SERVICE AWARD (F32)

Individual NRSA awards are given only at the postdoctoral level. The application must describe a specific research project that is guided and sponsored by a preceptor at a particular institution. This support is for full-time research training. Provisions of these awards include:

- Awards for up to 36 months of training (waivers may be granted to M.D.s for an additional year);
- Stipends based on years of experience: range is $17,000 - $31,500 per year;
- Institutional allowance of $3,000 per year ($2,000 per year for fellows at NIH) to help meet expenses;
- Support for more than 12 months requires "payback."

B. SENIOR NATIONAL RESEARCH SERVICE AWARD (F33)

Senior fellowships are designed for experienced scientists who wish to make major changes in the direction of their research career, to broaden their research capabilities, or to enlarge their command of an allied research field. Provisions of the award include:

- Awards may be for up to 24 months;
- Candidates must have received a doctoral degree or equivalent and have had at least 7 subsequent years of relevant professional or research experience;
- The stipend is up to $31,500 per year.

APPLICATION SUBMISSION AND REVIEW FOR FELLOWSHIP AWARDS

Application Receipt Dates for these two awards are January 10, May 10, and September 10. Applicants must use Fellowship Application Kit (PHS 416-1, Revised 4/89). Fellowships will be reviewed through the accelerated NIH peer review system in the Division of Research Grants. Earliest possible funding start dates will be 7 to 8 months after receipt dates.

NOTE: The Division also supports approximately 41 predoctoral and 220 postdoctoral positions which are administered through Institutional Training Grants (T32s) at over 50 locations throughout the country. For information about applying for these grants or for a list of the currently active Training Grants supported by this Division, contact the representative listed at the end of this announcement.

C. PHYSICIAN SCIENTIST AWARD - PSA (K11)

The PSA is designed to encourage the newly trained clinician to develop independent research skills and experience in a fundamental science. The award is divided into two phases. During Phase I, which may last 2-3 years, the candidate is expected to develop independent research skills and experience in a fundamental science and may elect to work toward a Ph.D. degree. The primary sponsor must be an accomplished basic science investigator. Phase II entails intensive research activity, applying the skills learned during Phase I.

Applicants for the PSA must:

- Hold an M.D. or other health professional degree. Ordinarily, candidates holding the Ph.D. are ineligible;
- Have completed at least one postgraduate year of clinical training by the time the award is made;
- Not have previous independent research support;
- Commit at least 75 percent time to PSA activities.

Provisions of the PSA include:

- Three to five years of support, nonrenewable;
- Salary up to $50,000 per year plus fringe benefits;
Up to $10,000 (Phase I) and $20,000 (Phase II) per year for research supplies, equipment, technical assistance, travel, etc.;

Up to 10 percent of the primary sponsor's salary and commensurate fringe benefits during the first phase of the award.

Awardees must inform the NIH for each of five years following the completion of the award about academic status, publications, and research grants and contracts received.

D. CLINICAL INVESTIGATOR AWARD - CIA (K08)

The CIA is offered to provide the opportunity for promising clinically trained individuals with demonstrated aptitude in research to develop into independent investigators.

Applicants for the NIDDK CIA must:

Hold an M.D. or other health professional degree;

Have had approximately 4 to 8 years of postdoctoral experience, both clinical and research (a minimum of 2 years of each) by the projected start of the award;

Not have been a principal investigator on a Public Health Service-supported research project.

Provisions of the CIA include:

Three to five years of support, nonrenewable;

Salary up to $50,000 per year plus fringe benefits;

Up to $20,000 per year for research supplies, equipment, technical assistance, travel, etc.;

Commitment of at least 75 percent time to the project.

Awardees must inform the NIH for each of five years following the completion of the award about academic status, publications, and research grants and contracts received.

E. RESEARCH CAREER DEVELOPMENT AWARD - RCDA (K04)

The RCDA is a special salary grant to enhance the research capabilities of individuals in the formative stages of their careers. Candidates who have demonstrated outstanding potential as independent investigators in health-related research but need to be released from some of the teaching, clinical, and administrative duties assigned to junior faculty are eligible. The award is not intended for untried investigators or for those already established as an independent investigator.

Applicants for the RCDA must:

Hold a doctoral degree or equivalent and have at least 5 years postdoctoral research experience, including 2 years as the principal investigator of a peer-reviewed research grant, prior to the requested beginning date of the award;

Describe in the application how the award will enhance development as independent investigators;

Have independent research support, funded by the NIDDK, sufficient for the research proposed in the RCDA application;

Hold a faculty appointment.

Provisions of the RCDA include:

Five years of support, nonrenewable;

Salary up to $50,000 per year plus fringe benefits. No funds are available under this award for research expenses. These expenses are expected to be included in the independent research support described above.
Commitment of at least 80 percent time to research. The remaining time (up to 20 percent) must be spent on research-related activities that will enhance research career development.

RCDA applications may be submitted concurrently with a regular research grant application but may not be submitted concurrently with other development awards such as PSA, CIA, FIRST Award, or Academic Award.

APPLICATION SUBMISSION AND REVIEW for the K AWARDS

Application receipt dates for all career development awards (K series) are February 1, June 1, and October 1. The PSA and CIA applications will be reviewed by an NIDDK review committee. RCDA applications will be reviewed through the regular NIH peer review system in the Division of Research Grants. Earliest possible funding dates are approximately 10 months after the receipt dates. Use application form PHS 398, Rev. 10/88, with special instructions for the PSA, CIA, and RCDA ("The K Awards," October 1990).

Applications submitted in response to this announcement should be identified by typing PA-RESEARCH CAREER AWARDS in DDEM and PA-91-15 on line 2 of the face page, below the title of the project.

Applicants from institutions that have a General Clinical Research Center (GCRC) funded by the NIH National Center for Research Resources may wish to identify the GCRC as a resource for conducting the proposed activity. In such a case, a letter of agreement from either the GCRC program director or Principal Investigator could be included with the application.

For further information about these awards, contact:

Lois F. Lipsett, Ph.D.
Program Director
Division of Diabetes, Endocrinology, and Metabolic Diseases
Westwood Building, Room 620
Bethesda, MD 20892
Telephone: (301) 496-7433